Onyx, University of Texas M.D. Anderson Cancer Center deal

The university will conduct preclinical and clinical studies under a non-exclusive, two-year deal to research potential treatments for multiple myeloma (MM) and lymphoma, including Onyx's proteasome inhibitors carfilzomib and oprozomib (formerly ONX 0912). The partners said the deal will contribute to the biological understanding and clinical profile of the two products in the indications. The partners may combine the products with other novel therapies in earlier stages of development. A joint steering committee will manage the collaboration. Details were not disclosed. ...